Overview

Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans

Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
0
Participant gender:
Male
Summary
We hypothesized that short-term treatment with haloperidol induces insulin resistance through a mechanistic route that is independent of weight gain. We therefore treated healthy non-obese men with haloperidol for 8 days, and studied the impact of these intervention on glucose and lipid metabolism by hyperinsulinemic euglycemic clamp, isotope dilution technology and indirect calorimetry.
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Leiden University Medical Center
Collaborator:
Dutch Diabetes Research Foundation
Treatments:
Dopamine
Haloperidol
Haloperidol decanoate
Criteria
Inclusion Criteria:

- Healthy men

- 20 kg/m2 < BMI < 26 kg/m2

- Age 20-40 years

- FPG < 6 mmol/L

Exclusion Criteria:

- FPG > 6 mmol/L

- BMI > 26 kg/m2

- Psychiatric disorders and/or use of antipsychotic or antidepressants drugs at present
or in the past.

- A positive family history of schizophrenia

- Any significant chronic disease

- Renal, hepatic or endocrine disease

- Use of medication known to influence lipolysis and/or glucose metabolism

- Total cholesterol > 7mmol/L and/or triglycerides > 2 mmol/L

- Recent weight changes or attempts to loose weight (> 3 kg weight gain or loss, within
the last 3 months)

- Difficulties to insert an intravenous catheter

- Smoking (current)

- Severe claustrophobia (ventilated hood)

- Recent blood donation (within the last 2 months)

- Recent participation in other research projects (within the last 3 months),
participation in 2 or more projects in one year

- Extensive sporting activities (more than 10 hours of exercise per week)